Biologics

Regenerative medicine company Aziyo Biologics on June 29 launched OsteoGro V, a viable cell bone matrix to assist with bone repair.

Orthobiologics company Bioventus on June 25 launched its Signafuse bioactive bone graft in a strip format.

Here are four key developments in spinal biologics in the last month:

Biomaterials startup Spiderwort has closed a $3.4 million seed financing round one year after it secured $500,000 in a friends and family funding round, Betakit reports.

Minimally invasive spine therapy company SpineOvations reported favorable results at the midpoint of its DiscSeal clinical trial.

The European Commission recently approved Zolgensma, Novartis' $2.1 million gene therapy drug for spinal muscular atrophy, for infants and children up to 46 pounds.

Orthobiologics company Cerapedics published data from a clinical trial examining the fusion rate of its i-Factor bone graft in noninstrumented lumbar fusion.

The FDA on May 4 granted biotechnology company Alume Biosciences permission to investigate the use of a nerve imaging drug during spine surgery, Biospace reports.

The FDA granted Carmell Therapeutics Fast Track designation on April 27 for its debut product, a bone healing accelerant, OA Online reports.

Stefanos Theoharis, PhD, was appointed chief business officer of Bone Therapeutics on March 26.